News

Biovian and 3P Biopharmaceuticals Combine to Form 3PBIOVIAN

February 05, 2024

The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.

Novo Holdings to Acquire Catalent in Deal Valued at $16.5 billion

February 05, 2024

Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.

AbbVie Gains Nod from NICE for Tepkinly

February 04, 2024

NICE has recommended the use of AbbVie's Tepkinly as a treatment option for eligible adults with diffuse large B-cell lymphoma.

Latest Acquisition Sees ProductLife Group Expand its Asia-Pacific Footprint

February 03, 2024

ProductLife Group has announced its acquisition of Australian company Commercial Eyes.

EMA Given Grant to Support Establishment of African Medicines Agency

February 02, 2024

The agency will coordinate intra-regional medicines regulation to strengthen the African regulatory network.

Lonza and Oxford Nanopore Partner on mRNA Analytics

February 02, 2024

Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.

MHRA’s New International Recognition Procedure

February 02, 2024

The UK’s IRP increases flexibility and will help speed up product approvals and patient access to medicines.

On the Up and Up

February 02, 2024

The industry’s M&A activity is on the up and expected to continue to rise in 2024.

Agilent and Incyte Collaborate on Development of CDx in Hematology and Oncology

February 02, 2024

Agilent Technologies and Incyte have signed an agreement to collaborate on the development of companion diagnostics programs.

Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition

February 01, 2024

With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.